Masaya Yamauchi1, Norihiro Honda2, Hisanao Hazama1, Shoji Tachikawa3, Hiroyuki Nakamura4, Yasufumi Kaneda5, Kunio Awazu6. 1. Graduate School of Engineering, Osaka University. 2. Graduate School of Engineering, Osaka University; Institute for Academic Initiatives, Osaka University. 3. Synthetic Organic Division, Chemical Resources Laboratory, Tokyo Institute of Technology; Department of Life Science, Faculty of Science, Gakushuin University. 4. Synthetic Organic Division, Chemical Resources Laboratory, Tokyo Institute of Technology. 5. Graduate School of Medicine, Osaka University. 6. Graduate School of Engineering, Osaka University; Global Center for Medical Engineering and Informatics, Osaka University; Graduate School of Frontier Biosciences, Osaka University.
Abstract
BACKGROUND AND AIMS: There is an urgent need to develop an efficient strategy for the treatment of drug-resistant prostate cancer. Photodynamic therapy (PDT), in which low incident levels of laser energy are used to activate a photosensitizer taken up by tumor cells, is expected as a novel therapy for the treatment of prostate cancer because of the minimal invasive nature of PDT. The present study was designed to assess the efficacy of a novel vector approach combined with a conventional porphyrin-based photosensitizer. MATERIALS AND METHODS: Our group focused on a non-viral vector (hemagglutinating virus of Japan envelope; HVJ-E) combined with protoporphyrin IX (PpIX) lipid, termed the porphyrus envelope (PE). It has been previously confirmed that HVJ-E has drug-delivering properties and can induce cancer-specific cell death. The PE (HVJ-E contained in PpIX lipid) was developed as a novel photosensitizer. In this study, the antitumor and PDT efficacy of the PE against hormone-antagonistic human prostate cancer cells (PC-3) were evaluated. RESULTS AND CONCLUSIONS: Our results demonstrated that, under specific circumstances, PDT using the PE was very effective against PC-3 cells. A novel therapy for drug-resistant prostate cancer based on this vector approach is eagerly anticipated.
BACKGROUND AND AIMS: There is an urgent need to develop an efficient strategy for the treatment of drug-resistant prostate cancer. Photodynamic therapy (PDT), in which low incident levels of laser energy are used to activate a photosensitizer taken up by tumor cells, is expected as a novel therapy for the treatment of prostate cancer because of the minimal invasive nature of PDT. The present study was designed to assess the efficacy of a novel vector approach combined with a conventional porphyrin-based photosensitizer. MATERIALS AND METHODS: Our group focused on a non-viral vector (hemagglutinating virus of Japan envelope; HVJ-E) combined with protoporphyrin IX (PpIX) lipid, termed the porphyrus envelope (PE). It has been previously confirmed that HVJ-E has drug-delivering properties and can induce cancer-specific cell death. The PE (HVJ-E contained in PpIXlipid) was developed as a novel photosensitizer. In this study, the antitumor and PDT efficacy of the PE against hormone-antagonistic humanprostate cancer cells (PC-3) were evaluated. RESULTS AND CONCLUSIONS: Our results demonstrated that, under specific circumstances, PDT using the PE was very effective against PC-3 cells. A novel therapy for drug-resistant prostate cancer based on this vector approach is eagerly anticipated.
Entities:
Keywords:
Sendai virus; drug delivery; drug-resistant prostate cancer; photodynamic therapy